[1]王楷翔a,曹　明a,陈　晖b,等.HCV感染患者血清miR-199和miR-483水平表达及其临床价值[J].现代检验医学杂志,2021,36(05):58-61.[doi:10.3969/j.issn.1671-7414.2021.05.013]
　WANG Kai-xianga,CAO Minga,CHEN Huib,et al.Expression and Clinical Value of Serum miR-199 and miR-483 inPatients with HCV Infection[J].Journal of Modern Laboratory Medicine,2021,36(05):58-61.[doi:10.3969/j.issn.1671-7414.2021.05.013]
点击复制

HCV感染患者血清miR-199和miR-483水平表达及其临床价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年05期
页码:
58-61
栏目:
论　著
出版日期:
2021-10-14

文章信息/Info

Title:
Expression and Clinical Value of Serum miR-199 and miR-483 inPatients with HCV Infection
文章编号:
1671-7414（2021）05-058-04
作者:
王楷翔1a; 曹　明1a; 陈　晖1b; 赵　娟2
（1. 保定市人民医院a. 分子生物学实验室；b. 肝病科，河北保定 071000；2. 保定市第二中心医院检验科，河北涿州 072750）
Author(s):
WANG Kai-xiang1a;  CAO Ming1a;  CHEN Hui1b;  ZHAO Juan2
（1a. Molecular Biology Laboratory; 1b. Department of Hepatology, Baoding People’s Hospital，Hebei Baoding 071000,China；2. Department of Clinical Laboratory, the Second Central Hospital of Baoding, Hebei Zhuozhou 072750, China）
关键词:
丙型肝炎; 肝癌; 微小核糖核酸-199; 微小核糖核酸-483
分类号:
R512.63；R392.11
DOI:
10.3969/j.issn.1671-7414.2021.05.013
文献标志码:
A
摘要:
目的　探讨丙型肝炎病毒（HCV）感染患者血清miR-199及miR-483的表达，分析其对肝癌的诊断价值。方法　选取121例HCV感染患者和健康体检正常者50例作为研究对象，其中HCV感染患者分为慢性丙型肝炎（CHC）50例、肝硬化43例和肝癌28例。检测各组血清miR-199及miR-483表达水平和HCV-RNA含量。应用ROC曲线分析miR-199及miR-483对肝癌的诊断价值。Pearson相关分析miR-199与miR-483在HCV感染患者中的相关性。结果　肝癌组、肝硬化组和CHC组血清miR-199（3.40±1.25，1.83±0.72，1.70±0.65 vs 0.80±0.14）及miR-483（3.86±1.62，2.04±0.91，1.93±0.82 vs 0.71±0.08）表达水平均明显高于对照组，差异有统计学意义（t=11.904~16.825，均P<0.001）。肝癌组血清miR-199及miR-483表达水平均明显高于CHC组和肝硬化组，差异均有统计学意义（t=11.604~14.817，均P<0.001）。ROC曲线显示，miR-199及miR-483二者联合诊断肝癌的曲线下面积（0.922，95%CI：0.858～0.977）最大，其敏感度和特异度为93.7%和86.4%。相关性分析显示，肝癌患者血清miR-199表达水平与miR-483呈正相关（r=0.803，P<0.001）。结论　血清miR-199及miR-483水平在HCV感染患者中明显升高，二者联合对诊断HCV感染导致的肝癌具有较好的诊断价值。
Abstract:
Objective　To investigate the expression of serum miR-199 and miR-483 in patients with hepatitis C virus (HCV)infection and analyze their diagnostic value for liver cancer. Methods　The 121 patients with HCV infection and 50 healthypeople were selected as the research objects. The patients with HCV infection were divided into 50 cases of chronic hepatitis C(CHC), 43 cases of liver cirrhosis and 28 cases of liver cancer. The expression levels of serum miR-199 and miR-483 and thecontent of HCV-RNA in each group were detected. ROC curve was used to analyze of miR-199 and miR-483 in the diagnosisof liver cancer. Pearson correlation analysis were used to analyze the correlation between miR-199 and miR-483 in HCVinfected patients. Results　The expression levels of miR-199（3.40±1.25，1.83±0.72，1.70±0.65 vs 0.80±0.14） andmiR-483（3.86±1.62，2.04±0.91，1.93±0.82 vs 0.71±0.08） in liver cancer group, cirrhosis group and CHC group weresignificantly higher than those in the control group, the differences were statistically significant(t=11.904~16.825, all P<0.001).The expression levels of miR-199 and miR-483 in liver cancer group were significantly higher than those in CHC group andcirrhosis group, the differences were statistically significant(t=11.604~14.817, all P<0.001). ROC curve showed that the areaunder curve (0.922, 95%CI：0.858~0.977) of the combined diagnosis of liver cancer with miR-199 and miR-483 were thelargest, and its sensitivity and specificity were 93.7% and 86.4%, respectively. Correlation analysis showed that the expressionlevel of serum miR-199 in liver cancer group was positively correlated with miR-483 (r=0.803，P<0.001). Conclusion　Theexpression levels of serum miR-199 and miR-483 in patients with HCV infection increased significantly, and the combination ofthe two has a good value in the diagnosis of liver cancer caused by HCV infection.

参考文献/References:

[1] 陈仲丹．全球丙型肝炎消除的进展、挑战及应对[J].中华肝脏病杂志,2020,28(10):812-816.CHEN Zhongdan. Progress, challenges andcountermeasures of global hepatitis C elimination [J].Chinese Journal of Hepatology, 2020, 28 (10): 812-816.
[2] KAPLAN D. Hepatitis C virus[J]. Annals of InternalMedicine, 2020, 173(5): ITC33-ITC48.
[3] CABRAL B C A, HOFFMANN L, BOTTARO T, et al.Circulating microRNAs associated with liver fibrosisin chronic hepatitis C patients[J]. Biochemistry andBiophysics Reports, 2020, 24(9): 100814.
[4] WEIS A, MARQUART L，CALVOPINA D A. SerummicroRNAs as biomarkers in hepatitis C: preliminaryevidence of a microRNA panel for the diagnosis ofhepatocellular carcinoma[J]. International Journal ofMolecular Sciences, 2019, 20(4): 864.
[5] MOURAD L, EL-AHWANY E, ZOHEIRY M, etal. Expression analysis of liver-specific circulatingmicroRNAs in HCV-induced hepatocellular Carcinomain Egyptian patients[J]. Cancer Biology & Therapy,2018, 19(5): 400-406.
[6] GAILHOUSTE L, LIEW L C, YASUKAWA K, et al.MEG3-derived miR-493-5p overcomes the oncogenicfeature of IGF2-miR-483 loss of imprinting in hepaticcancer cells[J]. Cell Death & Disease, 2019, 10(8): 553.
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019 年版)[J]. 中华传染病杂志,2020,38(1):9-28.Chinese Society of Hepatology, Chinese Society ofInfectious Diseases, Chinese Medical Association.Guidelines for the prevention and treatment of hepatitisC (2019 version) [J]. Chinese Journal of InfectiousDiseases, 2020, 38 (1): 9-28.
[8] LI Jian, JIN Boxun, WANG Tiezheng ,et al.Serum microRNA expression profiling identifiesserum biomarkers for HCV-related hepatocellularcarcinoma[J]. Cancer Biomarkers : Section A ofDisease Markers, 2019, 26(4): 501-512.
[9] 邱颖谦，陈永林．微小RNA (microRNA) 在肝细胞肝癌发生发展中的作用研究进展[J]. 基因组学与应用生物学, 2020, 39 (1): 485-490.QIU Yingqian，CHEN Yonglin. Advances in the roleof microRNA during the development of hepatocellularcarcinoma [J]. Genomics and Applied Biology, 2020,39 (1): 485-490.
[10] CHEN Qinlian, XIE Chunfeng, FENG Kunliang, et al.microRNAs carried by exosomes promote epithelialmesenchymaltransition and metastasis of liver cancercells[J]. American Journal of Translational Research,2020, 12(10): 6811-6826.
[11] EL-HEFNY M, FOUAD S, HUSSEIN T, et al.Circulating microRNAs as predictive biomarkersfor liver disease progression of chronic hepatitis C(genotype-4) Egyptian patients[J]. Journal of MedicalVirology, 2019, 91(1): 93-101.
[12] TANG Shaohui, CHEN Yanfang, FENG Shufen, etal. MiR-483-5p promotes IGF-II transcription andis associated with poor prognosis of hepatocellularcarcinoma[J]. Oncotarget, 2017, 8(59): 99871-99888.
[13] PEZZUTO F, BUONAGURO L, BUONAGURO F M,et al. The role of circulating free DNA and microRNAin non-invasive diagnosis of HBV- and HCV-relatedhepatocellular carcinoma[J]. International Journal ofMolecular Sciences, 2018, 19(4): 1007.
[14] LU Xinyuan, CHEN Di, GU Xiaoyuan, et al. Predictingvalue of ALCAM as a target gene of microRNA-483-5p in patients with early recurrence in hepatocellularcarcinoma[J]. Frontiers in Pharmacology, 2017, 8: 973.
[15] JIAO Xiaoyang, FAN Zhicheng, CHEN Huanzhu, et al. Serumand exosomal miR-122 and miR-199a as a biomarker topredict therapeutic efficacy of hepatitis C patients[J]. Journal ofMedical Virology, 2017, 89(9): 1597-1605.
[16] HASSAN A S, ELGENDY N A, TAWFIK N, et al.Serum miR-483-5p and miR-133a as biomarkers fordiagnosis of hepatocellular carcinoma Post-HepatitisC infection in Egyptian patients[J]. The EgyptianJournal of Immunology / Egyptian Association ofImmunologists, 2019, 26(2): 31-40.

相似文献/References:

[1]王芳胜,熊敦勇,寇辉,等.血清AFP，CEA，CA-199与TAP在肝癌诊断中的应用价值[J].现代检验医学杂志,2015,30(05):148.[doi:10.3969/j.issn.1671-7414.2015.05.047]
　WANG Fang-sheng,XIONG Dun-yong,KOU Hui,et al.Application Value of Serum AFP，CEA，CA-199 and TAP in the Diagnosis of Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(05):148.[doi:10.3969/j.issn.1671-7414.2015.05.047]
[2]黄启强,黄丽庆,周青,等.探讨CD4+CD25+Foxp3+调节性T淋巴细胞在HCV早期感染的作用[J].现代检验医学杂志,2015,30(06):64.[doi:10.3969/j.issn.1671-7414.2015.06.018]
　HUANG Qi-qiang,HUANG Li-qing,ZHOU Qing,et al.Study or Role of the CD4+CD25+Foxp3+ Regulatory T Lymphocytes in the Early Infection of HCV[J].Journal of Modern Laboratory Medicine,2015,30(05):64.[doi:10.3969/j.issn.1671-7414.2015.06.018]
[3]刘冲,唐浩,邓霖,等.血清miRNA-186,miRNA-30c在肝细胞性癌中诊断价值的研究[J].现代检验医学杂志,2016,31(06):44.[doi:10.3969/j.issn.1671-7414.2016.06.012]
　LIU Chong,TANG Hao,DENG Lin,et al.Research of Diagnostic Application of Serum miRNA-186 and miRNA-30c in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(05):44.[doi:10.3969/j.issn.1671-7414.2016.06.012]
[4]薛 丽,黄 芳,张彦平,等.丙肝患者血清HCV-RNA含量与肝功能及血常规指标的相关性[J].现代检验医学杂志,2017,32(05):110.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　XUE Li,HUANG Fang,ZHANG Yan-ping,et al.Relevance of Serum HCV-RNA Level with Routine Liver Function Indices and Blood Routine Parameters in Patients with Hepatitis C[J].Journal of Modern Laboratory Medicine,2017,32(05):110.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[5]王 蓉,蔡高涛,钟小青,等.血清AFP-L3和GP-73联合检测对原发性肝癌诊断的Meta分析[J].现代检验医学杂志,2019,34(02):72.[doi:10.3969/j.issn.1671-7414.2019.02.019]
　WANG Rong,CAI Gao-tao,ZHONG Xiao-qing,et al.Meta Analysis of Combined Detection of Serum AFP-L3and GP-73 in Diagnosis of Primary Liver Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):72.[doi:10.3969/j.issn.1671-7414.2019.02.019]
[6]张鑫浩,张涛元,李 俏,等.基于GEO 芯片数据的肝癌关键生物标志物的筛选与鉴定及生物信息学分析[J].现代检验医学杂志,2020,35(04):26.[doi:10.3969/j.issn.1671-7414.2020.04.007]
　ZHANG Xin-hao,ZHANG Tao-yuan,LI Qiao,et al.Screening, Identification and Bioinformatics Analysis of Key Biomarkers for Hepatocellular Carcinoma Based on GEO Chip Data[J].Journal of Modern Laboratory Medicine,2020,35(05):26.[doi:10.3969/j.issn.1671-7414.2020.04.007]
[7]陈　偲,王　颖a,谢生茂,等.GPRC5A对肝癌细胞增殖、凋亡和氧化应激的影响及作用机制探讨[J].现代检验医学杂志,2021,36(06):10.[doi:10.3969/j.issn.1671-7414.2021.06.003]
　CHEN Si,WANG Ying,WU Jian-jun,et al.Effects of GPRC5A on Proliferation, Apoptosis and Oxidative Stress of Hepatocellular Carcinoma Cells and Its Mechanism[J].Journal of Modern Laboratory Medicine,2021,36(05):10.[doi:10.3969/j.issn.1671-7414.2021.06.003]
[8]魏　英,王小林.肝癌组织中lncRNA-PRR34-AS1的表达特性及其对肝癌细胞增殖、迁移的影响和潜在分子机制[J].现代检验医学杂志,2021,36(06):41.[doi:10.3969/j.issn.1671-7414.2021.06.008]
　WEI Ying,WANG Xiao-lin.Expression Characteristics of lncRNA-PRR34-AS1 in Liver Cancer Tissues and Its Effects on Proliferation and Migration of Liver Cancer Cells and Potential Molecular Mechanism[J].Journal of Modern Laboratory Medicine,2021,36(05):41.[doi:10.3969/j.issn.1671-7414.2021.06.008]
[9]吴　琼,郑志存.UBE2T对肝癌细胞增殖、克隆形成及细胞周期的影响及机制研究[J].现代检验医学杂志,2022,37(02):115.[doi:10.3969/j.issn.1671-7414.2022.02.024]
　WU Qiong,CHENG Zhi-cun.Effects of UBE2T on Proliferation, Clone Formation and Cell Cycle of Hepatocellular Carcinoma Cells and Its Molecular Mechanism[J].Journal of Modern Laboratory Medicine,2022,37(05):115.[doi:10.3969/j.issn.1671-7414.2022.02.024]
[10]王俊霞a,贾如江b,霍浩然b,等.肝癌患者血清AHSG，NF-κB表达水平与肝动脉化疗栓塞术预后的相关性研究[J].现代检验医学杂志,2022,37(02):126.[doi:10.3969/j.issn.1671-7414.2022.02.026]
　WANG Jun-xiaa,JIA Ru-jiangb,HUO Hao-ranb,et al.Correlation between Serum AHSG, NF-κB Expression Levels and Prognosis of Hepatic Artery Chemoembolization in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(05):126.[doi:10.3969/j.issn.1671-7414.2022.02.026]

备注/Memo

备注/Memo:
基金项目：保定市科学计划与发展指导计划项目（18ZF043）。
作者简介：王楷翔（1980-）, 男，本科，副主任检验师，主要从事感染性疾病检验诊断研究，E-mail：yunyan-w@163.com。
更新日期/Last Update: 1900-01-01